We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-8.9%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$525M
AUM Growth
-$493M
Cap. Flow
-$400M
Cap. Flow %
-76.25%
Top 10 Hldgs %
41.99%
Holding
85
New
22
Increased
4
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$18.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.7M
3
COR icon
Cencora
COR
+$9.87M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$8.59M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.4M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$33.8M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$29.5M
3
ACHC icon
Acadia Healthcare
ACHC
+$26.1M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$25.4M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 90.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
51
DELISTED
Kezar Life Sciences
KZR
$2.45M 0.47%
502,600
– –
AKRO
52
DELISTED
Akero Therapeutics
AKRO
$2.31M 0.44%
57,000
-25,000
-30% -$1.06M
SLNO
53
DELISTED
Soleno Therapeutics
SLNO
$2.29M 0.44%
+32,000
New +$1.56M
CAPR icon
54
Capricor Therapeutics
CAPR
$380M
$2.27M 0.43%
+239,000
New +$3.32M
LXEO icon
55
Lexeo Therapeutics
LXEO
$338M
$2.24M 0.43%
+645,000
New +$2.86M
VERA icon
56
Vera Therapeutics
VERA
$2.32B
$2.19M 0.42%
91,000
-9,000
-9% -$289K
RGNX icon
57
Regenxbio
RGNX
$615M
$1.86M 0.35%
260,000
-272,000
-51% -$2.02M
IONS icon
58
Ionis Pharmaceuticals
IONS
$9.12B
$1.81M 0.35%
+60,000
New +$1.96M
MIRM icon
59
Mirum Pharmaceuticals
MIRM
$6.62B
$1.8M 0.34%
40,000
-626,200
-94% -$29.5M
NAMS icon
60
NewAmsterdam Pharma
NAMS
$3.24B
$1.39M 0.27%
68,000
-286,000
-81% -$6.36M
AGL icon
61
Agilon Health
AGL
$1.58B
$1.32M 0.25%
+12,204
New +$1.06M
SCYX icon
62
SCYNEXIS
SCYX
$36.7M
$1.17M 0.22%
153,614
– –
PCVX icon
63
Vaxcyte
PCVX
$7.68B
$868K 0.17%
+23,000
New +$1.84M
KPTI icon
64
Karyopharm Therapeutics
KPTI
$154M
$503K 0.1%
134,566
-1
-0% -$9
ELVN icon
65
Enliven Therapeutics
ELVN
$3.75B
$222K 0.04%
+11,300
New +$243K
HYPR icon
66
Hyperfine
HYPR
$90.4M
$159K 0.03%
222,174
-966,004
-81% -$993K
RVPH
67
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$132K 0.03%
+6,900
New +$217K
ABBV icon
68
AbbVie
ABBV
$472B
– –
-80,700
Closed -$14.3M
ACHC icon
69
Acadia Healthcare
ACHC
$2.52B
– –
-658,000
Closed -$26.1M
ASND icon
70
Ascendis Pharma A/S
ASND
$16.6B
– –
-62,000
Closed -$8.54M
BLUE
71
DELISTED
bluebird bio
BLUE
– –
-81,555
Closed -$680K
BMY icon
72
Bristol-Myers Squibb
BMY
$130B
– –
-215,000
Closed -$12.2M
COGT icon
73
Cogent Biosciences
COGT
$6.69B
– –
-287,104
Closed -$2.24M
DYN icon
74
Dyne Therapeutics
DYN
$4.12B
– –
-96,000
Closed -$2.26M
ILMN icon
75
Illumina
ILMN
$29.1B
– –
-109,700
Closed -$14.7M
1 2
3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2025 Portfolio in Review

As of Q1 2025, Avidity Partners Management held 85 positions worth $525M, down 48% from $1.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management withdrew a net $400M in Q1 2025, closing 18 positions and reducing 37 holdings. Its most notable exit was Intuitive Surgical, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 99% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Beam Therapeutics worth $13.9M.

  • Avidity Partners Management's largest Q1 2025 buy was Beam Therapeutics: 709,517 shares worth $13.9M.
  • Avidity Partners Management added most to Regeneron Pharmaceuticals in Q1 2025, an estimated $11.7M increase.
  • Avidity Partners Management's biggest Q1 2025 reduction was Mirum Pharmaceuticals, cutting an estimated $29.5M.
  • Avidity Partners Management fully exited Intuitive Surgical in Q1 2025, selling an estimated $33.8M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $525M portfolio in Q1 2025.
  • Avidity Partners Management opened 22 new positions and closed 18 in Q1 2025.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $525M.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.